# Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site Application

> **NIH NIH UG1** · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2021 · $274,995

## Abstract

As a National Cancer Institute (NCI) Network Lead Academic Participating Site (NLAPS), Huntsman Cancer
Institute (HCI) will provide leadership and robust accruals for the National Clinical Trials Network (NCTN)
Program. As evidenced by our prior success as a NCI U10-funded NLAPS partner, the HCI NLAPS will
contribute to the development and conduct of clinical trials in association with SWOG, NRG Oncology, and
Alliance for Clinical Trials in Oncology (ALLIANCE) NCTN Groups, as well as substantial accrual to clinical
trials across the entire NCTN. The HCI NLAPS executive team is well-qualified and experienced in cooperative
group research. The PI, David Gaffney, MD, PhD, is a radiation oncologist with a long history of leadership and
participation in NCTN activities. HCI's faculty adds significantly to the leadership of the NCTN program through
participation on steering committees, task forces, and group activities. In the past four years, three HCI faculty
were national principal investigators (PIs, study chairs); two faculty members are national PIs of pending trials.
In 2015, HCI advanced to Comprehensive Cancer Center status, receiving an overall merit descriptor of
`Exceptional'. Housed at the University of Utah, the only academic medical center in the Mountain West, HCI
draws cancer clinical trial patients from across Utah, as well as from Idaho, Nevada, Montana, and Wyoming,
and provides near-exclusive access to this patient population. As a NLAPS, HCI will be a strong, committed,
and sustaining partner to the NCTN program as a cancer center characterized by expertise, leadership, and
active accrual. HCI will work vigorously to ensure the success of the NCTN's cooperative endeavors to
eradicate cancer. HCI has a vigorous and growing clinical trials program, with strong commitment from the
University of Utah, substantial philanthropic support, state-of-the-art facilities, a dedicated Cancer Hospital, and
a centralized infrastructure for its clinical research enterprise housed in new, contiguous space. Our Center
also has unique assets of value to clinical research, including rural and Native American populations, an NCI
Center for Quantitative Imaging Excellence, and the Utah Population Database, a powerful interlinkage of
population based genealogical data and statewide medical and vital records.
HCI has demonstrated its strong commitment to participate in NCTN trials. In the year 2020 (as of Oct 31),
23% (129/543) of HCI therapeutic accruals were to NCTN trials. More than 59 NCTN therapeutic trials are
currently open to accrual, including rare disease trials. Further, UG1 Grant Year 2 NCTN trials saw an increase
in the median accrual to 10 patients per month, this exceeds the High Performance target and base award set
for HCI. We request supplemental funding for Grant Year 1 to support the higher accrual rates.

## Key facts

- **NIH application ID:** 10299442
- **Project number:** 3UG1CA233178-02S1
- **Recipient organization:** UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH
- **Principal Investigator:** David K Gaffney
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $274,995
- **Award type:** 3
- **Project period:** 2019-03-15 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10299442

## Citation

> US National Institutes of Health, RePORTER application 10299442, Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site Application (3UG1CA233178-02S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10299442. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*